After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.
Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
The industry’s most advanced oncolytic virus project, Pexa-Vec, faces a make-or-break pivotal study readout.
Funds backed by drugmakers remain visible contributors to the venture world, but several of the big corporate names seem to have reined in spending.
Amgen has set the stage for low-hassle access to new cholesterol-lowering agents, leaving little choice for competitors.
In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.
An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
Of the five biggest products set to lose exclusivity in the US this year the Swiss pharma giant owns three: Avastin, Herceptin and Tarceva.